SGLT-2 inhibitor Clinical Trials

4 actively recruiting trials across 1 location

▲ +2 trials since June 2026

Also known as: Empagliflozin, Sodium-glucose cotransporter-2 (SGLT2) inhibitors

Pipeline

Phase 1: 2Phase 4: 1

Top Sponsors

Sheffield Teaching Hospitals NHS Foundation Trust1
McGill University1
Larry W. Markham1
Kyungsub Song1

Indications

Heart Disease3
Valvular Cardiomyopathy1
Heart Failure Due to Coronary Artery Disease1
Duchenne Muscular Dystrophy (DMD)1
Heart Failure With Preserved Ejection Fraction (HFPEF)1

Other3 trials

Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors

Phase 1

Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

Phase 4

The Use of Advanced Imaging in HFpEF

Nashville, Tennessee1 trial

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

Vanderbilt University Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.